Galapagos N.V. Asset Resilience Ratio

Latest as of March 2026: 86.45%

Galapagos N.V. asset resilience ratio. Galapagos N.V. (GLPG) has an Asset Resilience Ratio of 86.45% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GLPG defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€2.92 Billion
≈ $3.41 Billion USD Cash + Short-term Investments

Total Assets

€3.37 Billion
≈ $3.94 Billion USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Galapagos N.V. (2014–2025)

Asset resilience ratio of Galapagos N.V. from 2014 to 2025. This chart shows how Galapagos N.V.'s Asset Resilience Ratio has changed over time. Read GLPG liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Galapagos N.V.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Galapagos N.V. assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €2.92 Billion 86.45%
Total Liquid Assets €2.92 Billion 86.45%

Asset Resilience Insights

  • Very High Liquidity: Galapagos N.V. maintains exceptional liquid asset reserves at 86.45% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Galapagos N.V. Industry Peers by Asset Resilience Ratio

Compare Galapagos N.V.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Galapagos N.V. Asset Resilience Ratio by Year (2014–2025)

Galapagos N.V. asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Galapagos N.V..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 85.43% €2.91 Billion
≈ $3.40 Billion
€3.41 Billion
≈ $3.98 Billion
+11.60pp
2024-12-31 73.83% €3.05 Billion
≈ $3.57 Billion
€4.14 Billion
≈ $4.84 Billion
-6.90pp
2023-12-31 80.73% €3.52 Billion
≈ $4.11 Billion
€4.36 Billion
≈ $5.09 Billion
+4.99pp
2022-12-31 75.74% €3.59 Billion
≈ $4.19 Billion
€4.73 Billion
≈ $5.53 Billion
+28.18pp
2021-12-31 47.56% €2.47 Billion
≈ $2.89 Billion
€5.19 Billion
≈ $6.07 Billion
-5.37pp
2020-12-31 52.93% €3.03 Billion
≈ $3.54 Billion
€5.72 Billion
≈ $6.68 Billion
-11.65pp
2019-12-31 64.58% €3.92 Billion
≈ $4.58 Billion
€6.07 Billion
≈ $7.09 Billion
+63.98pp
2016-12-31 0.61% €6.57 Million
≈ $7.68 Million
€1.08 Billion
≈ $1.27 Billion
-0.94pp
2015-12-31 1.55% €6.86 Million
≈ $8.02 Million
€442.51 Million
≈ $517.35 Million
-2.30pp
2014-12-31 3.85% €10.42 Million
≈ $12.18 Million
€270.47 Million
≈ $316.20 Million
--
pp = percentage points

About Galapagos N.V.

AS:GLPG Netherlands Biotechnology
Market Cap
$2.07 Billion
€1.77 Billion EUR
Market Cap Rank
#6872 Global
#48 in Netherlands
Share Price
€26.90
Change (1 day)
+4.67%
52-Week Range
€23.40 - €29.56
All Time High
€249.50
About

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory no… Read more